Geode Capital Management LLC Purchases 13,775 Shares of Labcorp Holdings Inc. $LH

Posted by Brenda Bartman on May 31st, 2026

Geode Capital Management LLC increased its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 0.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,137,010 shares of the medical research company’s stock after purchasing an additional 13,775 shares during the period. Geode Capital Management LLC’s holdings in Labcorp were worth $534,023,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Labcorp by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock worth $2,471,326,000 after purchasing an additional 37,197 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Labcorp by 20.0% in the 3rd quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after purchasing an additional 440,224 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Labcorp by 10.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,204,276 shares of the medical research company’s stock worth $554,728,000 after purchasing an additional 207,962 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Labcorp by 15.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Labcorp by 4.0% in the 3rd quarter. Bank of America Corp DE now owns 726,090 shares of the medical research company’s stock worth $208,431,000 after purchasing an additional 27,879 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. This represents a 5.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.84% of the company’s stock.

Analysts Set New Price Targets

LH has been the topic of a number of recent research reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Robert W. Baird set a $334.00 target price on Labcorp in a report on Friday, May 1st. Piper Sandler increased their price target on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and an average price target of $308.00.

View Our Latest Report on Labcorp

Labcorp Trading Down 1.0%

NYSE LH opened at $260.21 on Friday. The firm has a market capitalization of $21.34 billion, a P/E ratio of 23.05, a PEG ratio of 1.82 and a beta of 0.91. The business has a fifty day simple moving average of $263.22 and a 200 day simple moving average of $265.84. Labcorp Holdings Inc. has a 12 month low of $241.81 and a 12 month high of $293.72. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts predict that Labcorp Holdings Inc. will post 17.99 EPS for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp’s dividend payout ratio is presently 25.51%.

Labcorp Company Profile

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.